Table 3 Risk factors affecting nab-paclitaxel monotherapy related adverse events and efficacy outcomes by meta-regression analysis
Effect Index | Risk Factors | Coef. value | Std. Err. | T value | P value | 95% Confidence Interval |
|---|---|---|---|---|---|---|
Incidence of neutropenia 3/4 grade | Her-2 negative | −0.136 | 0.063 | −2.14 | 0.046 | −0.268 to −0.003 |
Incidence of leukopenia all grades | Treatment line | 0.366 | 0.148 | 2.48 | 0.056 | −0.014 to 0.746 |
Incidence of neuropathy 3/4 grade | Nab-paclitaxel dosage | 0.201 | 0.107 | 1.87 | 0.078 | −0.025 to 0.427 |
Incidence of fatigue all grades | Treatment line | −0.239 | 0.100 | −2.40 | 0.032 | −0.455 to − 0.024 |
ORR | Treatment line | −0.180 | 0.059 | −3.03 | 0.006 | −0.302 to − 0.058 |
Nab-paclitaxel dosage | 0.171 | 0.081 | 2.11 | 0.044 | 0.005 to 0.338 | |
CBR | Treatment line | −0.176 | 0.077 | −2.29 | 0.037 | −0.340 to − 0.012 |
PFS | Treatment line | 1.398 | 0.635 | 2.20 | 0.045 | 0.036 to 2.760 |
Nab-paclitaxel dosage | 2.683 | 1.114 | 2.41 | 0.030 | 0.295 to 5.071 | |
OS | Treatment line | −18.909 | 8.210 | −2.30 | 0.040 | −36.797 to −1.021 |